Bristol-Myers Squibb, fighting off investor protests of its planned merger with Celgene, has won over the most influential advisers on Wall Street, improving the company’s odds of pulling off the $74 billion deal.

ISS and Glass Lewis, two powerful investment advisory services, endorsed the proposed deal Friday, siding with Bristol-Myers over dissident shareholders who argue that Celgene is too risky to justify the acquisition price. The firms’ coveted blessing comes weeks before the April 12 shareholder vote that will decide whether Bristol-Myers gets its way.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy